The global Rescue Inhaler Market is estimated to be valued at US$ 15.54 Bn in 2023 and is expected to exhibit a CAGR of 8.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

SWOT Analysis:-

·         Strengths: Wide product portfolio and strong brand image of major players. Growing incidences of asthma and COPD globally increases the demand for rescue inhalers.

·         Weaknesses: Higher costs associated with digital inhalers restricts its adoption in low and middle-income countries. Risk of medication overuse or underuse if not used properly.

·         Opportunities: Rising focus on development of combination rescue medications and smart/connected inhalers presents lucrative opportunities. Untapped potential in developing markets offer scope for market expansion.

·         Threats: Stringent regulations associated with respiratory drug approvals. Increased competition from generic drug manufacturers impacts profits of major players.

Key Takeaways:-

The global Rescue Inhaler Market is expected to witness high growth, exhibiting CAGR of 8.7% over the forecast period, due to increasing prevalence of respiratory diseases such as asthma and COPD globally.

Regional analysis: North America accounts for the largest share in the rescue inhaler market due to high healthcare spending and access to advanced treatment options. However, Asia Pacific region is poised to grow at a fastest pace during the forecast period owing to increasing pollution levels, smoking population and growing medical tourism in the region.

Key players operating in the rescue inhaler market include GlaxoSmithKline, Teva Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Pfizer, Sunovion Pharmaceuticals, Roche, 3M, Omron Healthcare, Philips.

Read More - https://www.feedsfloor.com/other/openup-new-avanue-rescue-inhaler-market